玻璃体后脱离对新生血管性年龄相关性黄斑变性治疗中雷珠单抗治疗与延长方案对比每月方案疗效的影响
该研究为随机对照临床试验的事后分析,纳入接受治疗与延长方案(n=265)或每月方案(n=264)雷珠单抗治疗12个月的新生血管性年龄相关性黄斑变性初治患者,评估完全性玻璃体后脱离(PVD)对疗效的影响。结果显示PVD对最佳矫正视力(BCVA)和中央视网膜厚度(CRT)变化无显著影响,但无完全性PVD患者在治疗与延长方案中所需注射次数更多且成功延长至超过8周的比例显著更低。
要点
- 治疗与延长组中,完全性PVD眼成功延长至超过8周的比例为71%,无PVD眼为55%(p=0.005)。
- 治疗与延长组中,完全性PVD眼注射次数中位数为8次,无PVD眼为9次(p=0.035)。
- 第12个月BCVA和CRT变化在有无PVD眼间均无显著差异。
核心结论
- PVD未发现影响治疗与延长方案雷珠单抗治疗的功能和解剖结局。
- 然而,无完全性PVD的患者需要更多次再治疗,且成功延长治疗间隔的可能性显著更低。
研究设计与样本
- 随机对照临床试验的事后分析,纳入初治新生血管性年龄相关性黄斑变性患者,随机接受治疗与延长方案(n=265)或每月方案(n=264)雷珠单抗治疗12个月。
- 由认证的设盲评分者对谱域光学相干断层扫描图像诊断完全性PVD的存在或缺失。
主要发现
- 基线时,每月方案组和治疗与延长组中完全性PVD的比例分别为51%和56%。
- 第12个月BCVA平均变化:每月治疗眼中,PVD眼+9.0字母 vs 无PVD眼+9.5字母(p=0.78);治疗与延长眼中,PVD眼+6.0字母 vs 无PVD眼+7.5字母(p=0.42)。
- 第12个月CRT平均变化:每月方案组中,PVD眼-174 µm vs 无PVD眼-173 µm(p=0.98);治疗与延长组中,PVD眼-175 µm vs 无PVD眼-164 µm(p=0.58)。
- 在治疗与延长患者中,注射次数中位数:PVD眼8次 vs 无PVD眼9次(p=0.035)。
- 在治疗与延长患者中,成功延长至超过8周的比例:PVD眼71% vs 无PVD眼55%(p=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the impact of posterior vitreous detachment (PVD) on the efficacy of treat-and-extend (T&E) ranibizumab in neovascular age-related macular degeneration. METHODS: In a post hoc analysis of a randomised controlled clinical trial, spectral-domain optical coherence tomography images of treatment-naïve patients randomised to receive T&E (n=265) or monthly (n=264) ranibizumab for 12 months were included. Certified, masked graders diagnosed the presence or the absence of complete PVD. The main outcome measures were the mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at month 12, the number of administered ranibizumab injections and the proportion of patients extended to more than 8 weeks. RESULTS: At baseline, complete PVD was present in 51% and 56% of patients in the monthly and T&E arms, respectively. Mean change in BCVA at month 12 was +9.0 (PVD) vs +9.5 letters (no PVD, p=0.78) in monthly treated eyes, and +6.0 (PVD) vs +7.5 letters (no PVD, p=0.42) in T&E treated eyes. Conversely, mean change in CRT at month 12 was -174 (PVD) vs -173 µm (no PVD, p=0.98) in the monthly arm, and -175 (PVD) vs -164 µm (no PVD, p=0.58) in the T&E arm. In T&E treated patients, the median number of injections was eight vs nine (p=0.035). 71% of PVD eyes were extended successfully, compared with 55% of eyes without PVD (p=0.005). CONCLUSION: PVD was not found to impact functional and anatomical outcomes of T&E ranibizumab therapy. However, patients without a complete PVD required more retreatments and were significantly less likely to be successfully extended. TRIAL REGISTRATION NUMBER: NCT01948830.
引用
- Waldstein SM, Coulibaly L, Riedl S, et al. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration. Br J Ophthalmol. 2019. PMID: 31563866. doi:10.1136/bjophthalmol-2019-314661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。